Interferon Beta-1A May Lessen Brain Atrophy in MS Patients
Specialists in neuroimaging at the University at Buffalo have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a standard treatment for MS, on brain atrophy is well known, but the process through which that occurs remains a mystery. UB scientists have shown that the treatment appears to limit atrophy by minimizing the toxic effect of pathologic iron deposits found in gray-matter structures of MS patients.